Skip to content

Detecting Generalized Tonic-Clonic Seizures With a Seizure Detection and Warning System in Epilepsy Patients

A Pivotal, Phase III Trial of Detecting Generalized Tonic-Clonic Seizures With a Seizure Detection and Warning System (System Version 1.5) in Epilepsy Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02371200
Enrollment
13
Registered
2015-02-25
Start date
2015-04-30
Completion date
2018-02-28
Last updated
2018-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy, Generalized Tonic-Clonic Seizures

Brief summary

Prospective study of an electromyography (EMG) based seizure detection and warning system for detecting generalized tonic-clonic (GTC) seizures.

Detailed description

This study A Pivotal, Phase III Trial of Detecting generalized tonic-clonic seizures with a Seizure Detection and Warning System in Epilepsy Patients is a phase III, pivotal, prospective study of an electromyography (EMG) based seizure detection and warning system (tentatively named Brain Sentinel™ Seizure Detection System) for detecting generalized tonic-clonic (GTC) seizures. The detection device is worn on the bicep brachii muscles and is intended to alert a remote caregiver of a GTC seizure and provide a record of GTC seizure activity. This is to facilitate a faster intervention to the GTC seizure, and to more accurately document GTC seizure frequency in a home, skilled nursing, or inpatient setting.

Interventions

The detection device is worn on the bicep brachii muscles and is intended to alert a remote caregiver of a GTC seizure and provide a record of GTC seizure activity.

Sponsors

Brain Sentinel
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

1. Subject has a history of GTC seizures, either primary GTC or partial onset seizures with secondary generalization. 2. Is being admitted to a hospital for routine vEEG monitoring related to seizures. 3. Male or female between the ages of 2-99. 4. Has an upper arm circumference which is adequate for proper fit of the EMG monitor (at least 14cm). 5. If female and of childbearing potential, has a negative pregnancy test. 6. Can understand and sign written informed consent, or will have a parent or a legally authorized representative (LAR) who can do so, prior to the performance of any study assessments. 7. Subject and/or Primary Caregiver must be competent to follow all study procedures. 8. Is able to read, speak, and understand English.

Exclusion criteria

1. Does not have a documented history of generalized seizures. 2. Has not had a GTC seizure within the last year AND is not expected to have a reduction of anti-epileptic drugs during their hospital admission. 3. Intracranial EEG electrodes are being used 4. The subject's upper arm circumference not adequate for proper fit of the EMG monitor (less than 14cm). 5. Pregnant female. 6. Subject/Caregiver is unable to provide consent.

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity of the Seizure Detection Systemup to 1 monthThe primary outcome measure for this clinical trial will be the sensitivity of the Brain Sentinel™ Seizure Detection Systems ability to detect GTC seizure activity in comparison to a Neurologist independent review of vEEG collected in an epilepsy monitoring unit.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026